487 related articles for article (PubMed ID: 26865349)
1. A retrospective comparison of infliximab versus adalimumab as induction and maintenance therapy for Crohn disease.
Varma P; Paul E; Huang C; Headon B; Sparrow MP
Intern Med J; 2016 Jul; 46(7):798-804. PubMed ID: 26865349
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and safety of either infliximab or adalimumab in 362 patients with anti-TNF-α naïve Crohn's disease.
Narula N; Kainz S; Petritsch W; Haas T; Feichtenschlager T; Novacek G; Eser A; Vogelsang H; Reinisch W; Papay P
Aliment Pharmacol Ther; 2016 Jul; 44(2):170-80. PubMed ID: 27226407
[TBL] [Abstract][Full Text] [Related]
3. Elective switching from infliximab to adalimumab in stable Crohn's disease.
Hoentjen F; Haarhuis BJ; Drenth JP; de Jong DJ
Inflamm Bowel Dis; 2013; 19(4):761-6. PubMed ID: 23446337
[TBL] [Abstract][Full Text] [Related]
4. Comparative Effectiveness of Infliximab Versus Adalimumab in Patients with Biologic-Naïve Crohn's Disease.
Benmassaoud A; Al-Taweel T; Sasson MS; Moza D; Strohl M; Kopylov U; Paradis-Surprenant L; Almaimani M; Bitton A; Afif W; Lakatos PL; Bessissow T
Dig Dis Sci; 2018 May; 63(5):1302-1310. PubMed ID: 29243105
[TBL] [Abstract][Full Text] [Related]
5. Treatment Persistence for Infliximab Versus Adalimumab in Crohn's Disease: A 14-Year Single-Center Experience.
Olivera P; Thiriet L; Luc A; Baumann C; Danese S; Peyrin-Biroulet L
Inflamm Bowel Dis; 2017 Jun; 23(6):976-985. PubMed ID: 28333755
[TBL] [Abstract][Full Text] [Related]
6. Comparison of medical costs among patients using adalimumab and infliximab: a retrospective study (COMPAIRS).
Sussman DA; Kubiliun N; Mulani PM; Chao J; Gillis CA; Yang M; Lu M; T Abreu M
Inflamm Bowel Dis; 2012 Nov; 18(11):2043-55. PubMed ID: 22241679
[TBL] [Abstract][Full Text] [Related]
7. A Retrospective Claims Database Study on Drug Utilization in Japanese Patients with Crohn's Disease Treated with Adalimumab or Infliximab.
Yokoyama K; Yamazaki K; Katafuchi M; Ferchichi S
Adv Ther; 2016 Nov; 33(11):1947-1963. PubMed ID: 27664107
[TBL] [Abstract][Full Text] [Related]
8. Benefit of infliximab reintroduction after successive failure of infliximab and adalimumab in Crohn's disease.
Gagniere C; Beaugerie L; Pariente B; Seksik P; Amiot A; Abitbol V; Allez M; Cosnes J; Sokol H
J Crohns Colitis; 2015 Apr; 9(4):349-55. PubMed ID: 25547977
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of infliximab and adalimumab for ambulatory Crohn's disease patients in primary gastroenterology centres.
Tursi A; Elisei W; Picchio M; Penna A; Lecca PG; Forti G; Giorgetti G; Faggiani R; Zampaletta C; Pelecca G; Brandimarte G
Eur J Intern Med; 2014 Jun; 25(5):485-90. PubMed ID: 24631020
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of adalimumab after infliximab failure in pediatric Crohn disease.
Fumery M; Jacob A; Sarter H; Michaud L; Spyckerelle C; Mouterde O; Savoye G; Colombel JF; Peyrin-Biroulet L; Gower-Rousseau C; Turck D;
J Pediatr Gastroenterol Nutr; 2015 Jun; 60(6):744-8. PubMed ID: 26000887
[TBL] [Abstract][Full Text] [Related]
11. Mucosal expression of basic fibroblastic growth factor, syndecan 1 and tumour necrosis factor-α in Crohn's disease in deep remission under treatment with anti-TNFα antibodies.
Tursi A; Elisei W; Principi M; Inchingolo CD; Nenna R; Picchio M; Giorgio F; Ierardi E; Brandimarte G
J Gastrointestin Liver Dis; 2014 Sep; 23(3):261-5. PubMed ID: 25267953
[TBL] [Abstract][Full Text] [Related]
12. Adalimumab and infliximab are equally effective for Crohn's disease in patients not previously treated with anti-tumor necrosis factor-α agents.
Kestens C; van Oijen MG; Mulder CL; van Bodegraven AA; Dijkstra G; de Jong D; Ponsioen C; van Tuyl BA; Siersema PD; Fidder HH; Oldenburg B;
Clin Gastroenterol Hepatol; 2013 Jul; 11(7):826-31. PubMed ID: 23376000
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of anti-TNF agents for Crohn's disease in a tertiary referral IBD practice.
Patil SA; Rustgi A; Langenberg P; Cross RK
Dig Dis Sci; 2013 Jan; 58(1):209-15. PubMed ID: 23014844
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcomes of patients with Crohn's disease who received infliximab or adalimumab as the first-line biologics.
Inokuchi T; Takahashi S; Hiraoka S; Toyokawa T; Takagi S; Takemoto K; Miyaike J; Fujimoto T; Higashi R; Morito Y; Nawa T; Suzuki S; Nishimura M; Inoue M; Kato J; Okada H
J Gastroenterol Hepatol; 2019 Aug; 34(8):1329-1336. PubMed ID: 30724387
[TBL] [Abstract][Full Text] [Related]
15. Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study.
Barberio B; Zingone F; D'Incà R; Rovigo L; Bertani L; Bodini G; Ghisa M; Gubbiotti A; Massimi D; Lorenzon G; Savarino EV
Clin Transl Gastroenterol; 2020 May; 11(5):e00177. PubMed ID: 32677808
[TBL] [Abstract][Full Text] [Related]
16. Adalimumab versus infliximab in treating post-operative recurrence of Crohn's disease: a national cohort study.
Preda CM; Fulger LE; Negreanu L; Manuc M; Sandra I; Diculescu MM
Rev Esp Enferm Dig; 2016 Oct; 108(10):642-647. PubMed ID: 27651132
[TBL] [Abstract][Full Text] [Related]
17. Experience with anti-TNF-α therapy for orofacial granulomatosis.
Elliott T; Campbell H; Escudier M; Poate T; Nunes C; Lomer M; Mentzer A; Patel P; Shirlaw P; Brostoff J; Challacombe S; Sanderson J
J Oral Pathol Med; 2011 Jan; 40(1):14-9. PubMed ID: 21249727
[TBL] [Abstract][Full Text] [Related]
18. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed.
Gisbert JP; Marín AC; McNicholl AG; Chaparro M
Aliment Pharmacol Ther; 2015 Apr; 41(7):613-23. PubMed ID: 25652884
[TBL] [Abstract][Full Text] [Related]
19. Direct retrospective comparison of adalimumab and infliximab in preventing early postoperative endoscopic recurrence after ileocaecal resection for crohn's disease: results from the MULTIPER database.
Kotze PG; Yamamoto T; Danese S; Suzuki Y; Teixeira FV; de Albuquerque IC; Saad-Hossne R; de Barcelos IF; da Silva RN; da Silva Kotze LM; Olandoski M; Sacchi M; Yamada A; Takeuchi K; Spinelli A
J Crohns Colitis; 2015 Jul; 9(7):541-7. PubMed ID: 25820017
[TBL] [Abstract][Full Text] [Related]
20. Does long-term efficacy differ between infliximab and adalimumab after 1 year of continuous administration?: A STROBE-compliant retrospective cohort study.
Otake H; Matsumoto S; Mashima H
Medicine (Baltimore); 2017 Apr; 96(16):e6635. PubMed ID: 28422861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]